Lauwers G Y, Scott G V, Karpeh M S
Department of Pathology and Laboratory Medicine, University of Florida College of Medicine, Gainesville 32610-0275, USA.
Cancer. 1995 May 1;75(9):2209-13. doi: 10.1002/1097-0142(19950501)75:9<2209::aid-cncr2820750904>3.0.co;2-m.
bcl-2 protooncogene encodes for a 26 kD protein effective in inhibiting programmed cell death (apoptosis). Its expression has been noted in lymphomas and colonic, lung, and breast carcinomas. bcl-2 protein is believed to play a role in the gastric carcinogenic sequence where it has been demonstrated in dysplastic epithelium. To further study the role of bcl-2 protein in gastric carcinogenesis and tumor progression, an immunohistochemical study of bcl-2 expression in gastric adenocarcinomas and its relation to the histologic type, grade of differentiation, pT stage, lymph node status, and survival was performed.
Immunohistochemical staining using monoclonal bcl-2 protein antibody, clone 124, was performed on archival material.
Forty-six of the sixty-four adenocarcinomas (72%) showed bcl-2 staining with immunoreactivity in 75% of the tumor or more. No specific pattern in the distribution of labeling was seen. bcl-2 reactivity was significantly associated with adenocarcinomas of the intestinal morphotype. Forty-five of 51 intestinal-type tumors (88%) were immunoreactive versus only 1 of the "diffuse" tumors (7%) (P = 0.001). Within the intestinal-type adenocarcinomas, a trend of increasing prevalence of immunoreactivity with higher histologic grades was seen. No correlation between bcl-2 expression and pT stage, lymph node status, or survival was observed.
bcl-2 expression in gastric adenocarcinoma appears to be associated almost exclusively with the intestinal morphotype and to some extent is more prevalent in grade 3 tumors. No correlation was noted with the pT stage, lymph node status, and survival. Inhibition of apoptosis through bcl-2 protein expression appears to be specifically associated with promotion of intestinal-type gastric adenocarcinoma but does not appear to be active and/or correlated with tumor progression.
bcl-2原癌基因编码一种26kD的蛋白质，可有效抑制程序性细胞死亡（凋亡）。其表达已在淋巴瘤以及结肠癌、肺癌和乳腺癌中被发现。bcl-2蛋白被认为在胃癌发生序列中发挥作用，在发育异常的上皮组织中已证实有其存在。为进一步研究bcl-2蛋白在胃癌发生和肿瘤进展中的作用，对胃腺癌中bcl-2表达及其与组织学类型、分化程度、pT分期、淋巴结状态和生存率的关系进行了免疫组织化学研究。
使用克隆号为124的单克隆bcl-2蛋白抗体对存档材料进行免疫组织化学染色。
64例腺癌中有46例（72%）显示bcl-2染色，75%或更多肿瘤细胞有免疫反应性。未观察到标记分布的特定模式。bcl-2反应性与肠型腺癌显著相关。51例肠型肿瘤中有45例（88%）有免疫反应性，而“弥漫型”肿瘤中只有1例（7%）有免疫反应性（P = 0.001）。在肠型腺癌中，随着组织学分级升高，免疫反应性患病率有增加趋势。未观察到bcl-2表达与pT分期、淋巴结状态或生存率之间的相关性。
胃腺癌中bcl-2表达似乎几乎仅与肠型相关，且在某种程度上在3级肿瘤中更普遍。未发现与pT分期、淋巴结状态和生存率相关。通过bcl-2蛋白表达抑制凋亡似乎与肠型胃腺癌的发生特别相关，但似乎与肿瘤进展无关且不活跃。
